Survey of Ophthalmology
Volume 45 , Pages S347-S351 , May 2001

Mechanism of Action of Bimatoprost (Lumigan™)

  • Richard F Brubaker, MD

      Affiliations

    • Corresponding Author InformationReprint address: Richard F Brubaker, MD, 601 Memorial Parkway SW, Rochester, MN 55902

References 

  1. In:  Hart WM editors. Adler's Physiology of the Eye. ed 9. St. Louis: Mosby; 1992;p 261
  2. Aronowitz JD, Brubaker RF. Effect of intraocular gas on intraocular pressure. Arch Ophthalmol. 1976;94:1191–1196
  3. Bárány EH. A pharmacologist looks at medical treatment in glaucoma—in retrospect and in prospect. Ophthalmology. 1947;86:80–94
  4. Bill A. Conventional and uveo-scleral drainage of aqueous humour in the cynomolgus monkey (Macaca irus) at normal and high intraocular pressures. Exp Eye Res. 1966;5:45–54
  5. Brandt J for the HTL™ Study Group I: Phase III, 3-month comparison of timolol with AGN 192024: a new Ocular Hypotensive Lipid (HTL™) for glaucoma management [abstract]. American Academy of Ophthalmology Annual Meeting, 2000
  6. Brown B, Burton P, Mann S, Parisi A. Fluctuations in intra-ocular pressure with sleep (II. Time course of IOP decrease after waking from sleep). Ophthalmic Physiol Opt. 1988;8:249–252
  7. Brubaker RF, Schoff EO, Nau CB, et al.  Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics (1). Am J Ophthalmol. 2001;131:19–24
  8. Goldmann H. Abflussdruck, Minutenvolumen und Widerstand der Kammerwasserstromung des Menschen. Doc Ophthalmol. 1951;5:278–356
  9. Grant WM. Clinical measurements of aqueous outflow. AMA. Arch Ophthalmol. 1951;46:113–131
  10. Grant WM. Tonographic method for measuring the facility and rate of aqueous flow in human eyes. AMA. Arch Ophthal. 1950;44:204–214
  11. Ingram CJ, Brubaker RF. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. Am J Ophthalmol. 1999;128:292–296
  12. Jones RF, Maurice DM. New methods of measuring the rate of aqueous flow in man with fluorescein. Exp Eye Res. 1966;5:208–220
  13. Maus TL, Nau C, Brubaker RF. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents. Arch Ophthalmol. 1999;117:586–591
  14. Reiss GR, Brubaker RF. The mechanism of betaxolol, a new ocular hypotensive agent. Ophthalmology. 1983;90:1369–1372
  15. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128:8–14
  16. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297–1304
  17. Toris CB, Tafoya ME, Camras CB, Yablonski ME. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology. 1995;102:456–461
  18. VanDenburgh AM, Laibovitz RA, Felix C. A novel ocular hypotensive lipid (Initial safety and efficacy of AGN 192024). Invest Ophthalmol Vis Sci. 1998;39(Suppl):S258
  19. Woodward DF, Krauss AH, Chen J, et al.  Replacement of the carboxylic acid group of prostaglandin F(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compounds. Br J Pharmacol. 2000;130:1933–1943
  20. Woodward DF, Tang-Liu DDS, Madhu C, et al: Prostaglandin F2α (PGF2α) 1-ethanolamide: a pharmacologically unique local hormone synthesized from anandamide [abstract]. 11th International Conference on Advances in Prostaglandin and Leukotriene Research, 2000
  21. Yablonski ME, Zimmerman TJ, Waltman SR, Becker B. A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res. 1978;27:135–142
  22. Zeimer RC, Wilensky JT, Gieser DK. Presence and rapid decline of early morning IOP peaks in glaucoma patients. Ophthalmology. 1990;97:547–550

PII: S0039-6257(01)00213-2

Survey of Ophthalmology
Volume 45 , Pages S347-S351 , May 2001

Article Tools

* Image Usage & Resolution